Seeking Alpha

onecardchuck

onecardchuck
Send Message
View as an RSS Feed
View onecardchuck's Comments BY TICKER:
Latest  |  Highest rated
  • The Future Of Omega-3 Based Lipid Management: All Eyes On Amarin [View article]
    Steve,

    Great article clear and to the point what a refreshing read from all the lies and manipulation posted.

    I have one more thing to add about Krill Oil that is a side effect I experienced when taking Neptune Krill Oil packaged and sold by NOW foods. I had taken it for over 8 months and noticed shortly after starting to take Krill Oil (unknown to me at the time) my sex drive was dropping and dropping to eventually become almost none existent. I starting taking note of my diet, vitamins and supplements. I first noticed my vitamins were expired and threw out all of them and replaced them with new fresh ones and after a month I still noticed my sex drive was nil. I them stopped taking Krill Oil and it took about 3 to 4 weeks and I then noticed my sex drive returning. I did do a search online about Krill Oil and libido and did find I am not the only to have experienced this. Just an FYI.
    May 31, 2013. 08:40 AM | 8 Likes Like |Link to Comment
  • All Eyes Now Focusing On Acquisition Of Amarin [View instapost]
    Iam,
    That point would be a valid one in many case with many drugs, but not here. Why you ask? Because we are competing against GSK which has a lot of cash but yet we are growing and they are shrinking. Hence, the better medicine will always win out and sell itself and by the time AZN/Omthera get on the scene we will be well established as the one to beat. I just don't see how Epanova could top Vascepa and by then my guess is it would be Lipitor/Vascepa combo. I get why AZN did what they did was to get in the combo drug market cheap and fast, which will take some market share from Liptor/Vascepa but not enough to matter.
    May 30, 2013. 09:17 AM | Likes Like |Link to Comment
  • All Eyes Now Focusing On Acquisition Of Amarin [View instapost]
    Iam,
    Not enjoying the roller coaster ride I take it. This is what happens when you buck the trend and set off on your own. WS hates it when a company does not conform to the norm, but it is not everyday a drug like Vascepa is born. Know the science and your investment and you won't mind the bumpy ride so much. Remember it is the science and medicine that will win out as what you are seeing is the early stages of people seeing great result and jumping on board and yet with a paltry salesforce as you put it.

    Hope this helps,
    May 29, 2013. 09:41 AM | 1 Like Like |Link to Comment
  • All Eyes Now Focusing On Acquisition Of Amarin [View instapost]
    Steve,

    I agree with you. I take it as AZN got bumped out of the bid for Amarin but see's the value of a combo statin/EPA and bought second best just to lock down a piece of the huge pie that a combo drug can generate in this market. They must feel they can get it approved for Anchor indication but all this is a long way away.

    Question is who remains at the table with Amarin (those with deeper pockets) and will it be a partnership or a BO. Especially with all the supplier agreements in place. It will be interesting to say the least.

    I am still sticking with Pfizer as my guess and will go with your price target.
    May 28, 2013. 10:35 AM | 3 Likes Like |Link to Comment
  • Amarin's Fish Oil: Looking Beyond Triglycerides [View instapost]
    Gary,

    Once you take Vascepa for a few months and feel the effects and see your blood work results. Trust me you you will never again make the mistake of saying OTC can do what Vascepa can do for you. Because there is nothing else even close.

    Hope this helps,
    Apr 29, 2013. 11:00 PM | 1 Like Like |Link to Comment
  • Amarin Will Be Granted NCE [View instapost]
    Anytime second full week of May but usually on Friday which would be the 17th if not sooner.
    Apr 29, 2013. 02:31 AM | Likes Like |Link to Comment
  • Amarin Will Be Granted NCE [View instapost]
    Steve I agree totally after reading the chemical compositions posted by the FDA they have really differentiated us from Lovaza. Can I get an AMEN.
    Apr 27, 2013. 10:11 AM | 1 Like Like |Link to Comment
  • Amarin Set To Go After Expanded TG Market In Q4 2013! [View instapost]
    Here is a nice article I found here on seeking alpha that supports a lot of what Steve says and is a great read.

    http://seekingalpha.co...

    Hope this helps,
    Apr 24, 2013. 09:58 AM | 2 Likes Like |Link to Comment
  • By Adding Cost Effective Suppliers, Amarin Looks To Gain Market Share With Vascepa [View article]
    Gary,

    I just wanted to make one more point about your doctor. Please bear with me:

    You cannot get your doctor to prescribe you Vascepa because he wants to see an outcomes study before he will prescribe it. Well lets go through everything you stated about your doctor.

    1) Wants to see an outcome study before prescribing it and Vascepa has one called the Jelis study. Oh wait I know he is going to say I don't like that study because it was done open label. Well it is more than any OTC or PlusEPA or Lovaza have. Plus why not start his own investigation with his patients much like you to do his own research and take on it. It can't hurt and has no side effects and saves you money. Win Win Win.

    2) So instead of paying $25.00 for Vascepa you should spend $140 a month to get PlusEPA which is kinda close but not really. I would say he is not looking out for your wallet.

    3) So he tells you to just go get any OTC fish oil pill to get your trigs down below $135.00. There is no OTC fish oil pill that can be taken in the quantities and be as effective as Vascepa and cost less than $25.00 a month out there as well as you are taking your chances on the wheel of death with unregulated OTC fish oil due to possible contaminates.

    By the sounds of it he is not looking out for you the patients best interest reviewing the points I have made above. So there comes a point in a man's life where he must take control of his own life and find a new doctor who will work with you on your lipid profile, wallet, and overall well being due to anti-inflamation effects of Vascepa plain and simple. Oh I no he is a great doctor and part of a very highly respected group of doctors, but there is one big problem he has become to think headed to listen to you the patient which makes him a poor choice.

    Hope this helps and good luck,
    Apr 24, 2013. 09:31 AM | Likes Like |Link to Comment
  • OMTH IPO Bombs [View instapost]
    You are not kidding as it just broke into the 5's and I agree with you 100%.
    Apr 23, 2013. 05:40 PM | Likes Like |Link to Comment
  • OMTH IPO Bombs [View instapost]
    Wow down over 10% today alone I would say that is a definite flop.
    Apr 22, 2013. 09:01 PM | 1 Like Like |Link to Comment
  • My 5 Summer Stock Market Flings For 2013 [View article]
    Please do short AMRN cause if I can accumulate more at a lower price it will be much appreciated.
    Apr 19, 2013. 04:11 PM | Likes Like |Link to Comment
  • By Adding Cost Effective Suppliers, Amarin Looks To Gain Market Share With Vascepa [View article]
    ralphey and yazzbro I agree and you saved me some typing.

    Gary,

    That is a farce nothing works as well as Vascepa out there and you know it. Plus add in the anti-inflammation benefit and no fish burps or side effects and you have a winner.

    At the end of 2013 Vascepa will be most if not all insurance companies at Tier 2 so 6.80 is a bit high for 4 grams. With a $25.00 copay for 120 pills that calculates out to less than a dollar a day for 4 grams good luck getting any other dietary supplement that cheep and that you can take in 4 gram quantities with no side effects.

    If your cardiologist is a cowboy and does not prescribe a drug that is fda approved, cheaper and more effect than anything else available, and because he doesn't like the Jelis study. Then I again say stay with him and suffer or get a new doctor.

    Apr 19, 2013. 04:02 PM | Likes Like |Link to Comment
  • By Adding Cost Effective Suppliers, Amarin Looks To Gain Market Share With Vascepa [View article]
    Gary you stated "I said above " for the most part " because with CAD patients like myself they want TG's under 135 however they aren't willing to prescribe Lovaza ( risk of raising LDL cholesterol ) and won't prescribe Vascepa until they see outcome data from the Reduce it Trial ."

    So they want your TG's under 135 and don't want to raise your LDL so no lovaza and no dietary supplement can do that. Oh but wait Vascepa can and they wont prescribe it until Reduce it result I think once the FDA approves it for 200-500 that would be reason enough for most to prescribe if not sooner. Unless of course they want to be negligent with your health and that is where you the patient comes in and says I need a new doctor.
    Apr 19, 2013. 08:56 AM | Likes Like |Link to Comment
  • By Adding Cost Effective Suppliers, Amarin Looks To Gain Market Share With Vascepa [View article]
    Oh I wouldn't read to much into that. For the reason being the last two weeks have been spring break for kids and people take vacations so a slow down during this time is no surprise. As for the uptake in Lovaza that can be easily explained as an automatic refill of stock for a supplier. It is a bit to early to be able to tell much from the scripts and even how accurate they are.
    Apr 18, 2013. 04:44 PM | Likes Like |Link to Comment
COMMENTS STATS
40 Comments
21 Likes